Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ethris mRNA pandemic influenza vaccine
- Development stage
- Unknown
- Lead developer
- Ethris
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular, Intranasal
01
Overview
Ethris mRNA pandemic influenza vaccine (ETH53) is an investigational, next-generation mucosal mRNA vaccine designed for the prevention of pandemic influenza, specifically targeting the H5N8 influenza virus subtype. Developed by Ethris in collaboration with the European NOFLU consortium, the vaccine utilizes Ethris's proprietary Stabilized Non-Immunogenic mRNA (SNIM®RNA) and Stabilized NanoParticle (SNaP®) lipid nanoparticle (LNP) platforms, along with a proprietary stabilizer excipient to ensure room-temperature stability and resistance to shear stress during nebulization. Unlike traditional systemic vaccines, this candidate is designed for intranasal or inhaled administration to trigger a robust mucosal immune response directly in the respiratory tract, the primary entry point of the virus, thereby potentially preventing viral replication and reducing transmission. The program is supported by the European Health and Digital Executive Agency (HaDEA) under the EU4Health program.
- Other names
- Ethris mucosal pandemic influenza vaccineH5N8 mRNA vaccineH-5N8 mRNA vaccineH 5N8 mRNA vaccineNOFLU vaccine
02
Targets
RLR (RIG-I-like receptors)MHC I (MHC class I})HA (Hemagglutinin)
Beyond the preview
Go deeper on Ethris mRNA pandemic influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ethris mRNA pandemic influenza vaccine.